Turn Biotechnologies Enhances Tissue Targeting with ARMM Acquisition for Precision Therapies

Turn Biotechnologies Enhances Precision with ARMM Technology

In a groundbreaking move, Turn Biotechnologies, a leader in epigenetic reprogramming, has acquired the revolutionary ARMM (ARRDC1 Mediated Microvesicles) technology. This acquisition aims to improve access to tissue targets, significantly expanding the capabilities of their epigenetic therapies.

The ARMM technology facilitates targeted, non-viral vesicular delivery, which plays a crucial role in precision medicine. By partnering this technology with its existing eTurna™ LNP administration platform, Turn Bio can now effectively administer a wider range of therapeutic agents, including gene editors, proteins, and RNA therapies, enhancing the efficacy of its treatment options.

Expanding Therapeutic Horizons

The integration of ARMM technology expands the range of organs, tissues, and cells that can be treated safely and effectively using Turn Bio's therapies. Preclinical data indicates the successful administration of therapeutic agents to various tissues such as the retina, lungs, nervous system, liver, and spleen. This versatility holds promise for applications in ophthalmology, dermatology, and immunology.

The recent licensing deal secures Turn Biotechnologies the rights to the groundbreaking ARMM technology from Harvard University, along with associated assets from Cambridge-based Vesigen Therapeutics. The combination of ARMM and the existing eTurna™ platform enhances the company's ERA® technology, which leverages mRNA to produce proteins that can alter cellular epigenomes to combat aging-related conditions.

The Future of Epigenetic Therapies

Anja Krammer, CEO of Turn Biotechnologies, emphasizes that the ARMM technology is pivotal to their mission of harnessing the potential of epigenetics to redefine healthcare, especially concerning aging. This technology allows for rigorous precision in administering therapies when it's most needed. It also provides the capability to deliver larger, more diverse payloads, which include various therapeutic agents, optimizing treatment possibilities for patients.

“This unparalleled delivery capability positions Turn Bio at the forefront of regenerative medicine,” Krammer noted.

ARMM's Scientific Significance

The ARMM platform utilizes human-derived extracellular vesicles to transport signaling molecules between cells, a feature that was innovatively developed by Vesigen Therapeutics under the auspices of Harvard University. Importantly, these vesicles are designed for effective transport of therapeutic agents directly into cells, providing a novel administration method for epigenetic tools.

By ensuring targeted delivery with reduced off-target effects, ARMM technology addresses many of the limitations experienced by conventional delivery systems. It complements Turn Bio's eTurna™ platform, which employs a library of lipid nanoparticles for drug delivery, thus significantly broadening the therapeutic landscape of the company.

Accelerating Drug Development

With the addition of ARMM, Turn Biotechnologies is set to accelerate the development of its drug candidates targeting various medical indications. The focus will be on rejuvenating therapies through the skin, utilizing the eTurna platform in tandem with ARMM to enhance treatment effectiveness and patient outcomes. The combined technological capabilities of ARMM and the eTurna platform signify a substantial advancement in developing precise drug delivery systems critical for addressing age-related diseases.

Prominent investors have taken notice of Turn Biotechnologies’ advances, with major commitments from firms including Bayer Healthcare LLC, Morningside Group Ltd., and Alexandria Ventures, highlighting the industry's interest in their innovative approach to epigenetic therapy.

In Conclusion

Turn Biotechnologies is not only on a path to redefine how epigenetic therapies are delivered but also sets the stage for promising advancements in medical science. By merging ARMM with their already robust technology, they are poised to make significant strides in treating various conditions attributed to aging and beyond.